Estrella Immunopharma, Inc. ESLA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Estrella Immunopharma, Inc. (ESLA) is a healthcare company listed in the US with a market value of about $22M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -135%.
About Estrella Immunopharma
Estrella Immunopharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 5 years in our data.
Score: 0.8 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | -$13M | -$7M | -$11M | -$996104 | -$247718 |
| Free cash flow | -$2M | — | -$1M | — | — |
| EPS (diluted) | $-0.35 | $-0.27 | $-36.35 | — | $-1.52 |
| Net margin | — | — | — | — | — |
| ROIC | — | -135.1% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Estrella Immunopharma pay a dividend?
Not currently.
Is Estrella Immunopharma a good stock to buy?
We do not give buy or sell advice. Estrella Immunopharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.